{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:44:35Z","timestamp":1789145075248,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260628"],"award-info":[{"award-number":["82260628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20232ACB206042"],"award-info":[{"award-number":["20232ACB206042"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ctrv.2025.103014","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T23:18:43Z","timestamp":1755904723000},"page":"103014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Opportunities and challenges for non\u2013small cell lung cancer brain metastases in the immunotherapy era"],"prefix":"10.1016","volume":"140","author":[{"given":"Ying","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103014_b0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: a Systematic Review and Meta-Analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"Achrol","year":"2019","journal-title":"Brain metastases Nat Rev Dis Primers"},{"key":"10.1016\/j.ctrv.2025.103014_b0015","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2025.103014_b0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103014_b0050","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0055","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0065","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0075","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103014_b0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/imt-2018-0049","article-title":"\u03b1-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8+ T-cell infiltration","volume":"11","author":"Wang","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2025.103014_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005248","article-title":"Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination","volume":"10","author":"Van der Woude","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic Radiation Therapy Augments Antigen-specific PD-1-Mediated Antitumor Immune responses via Cross-Presentation of Tumor Antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0100","article-title":"Outcomes with Pembrolizumab Monotherapy in patients with Programmed Death-Ligand 1\u2013Positive NSCLC with Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ctrv.2025.103014_b0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cllc.2021.02.001","article-title":"Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (\u2265 50%) NSCLC: Real-world results with special Focus on PS \u2265 2, Brain Metastases, and Steroids","volume":"22","author":"Frost","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crin\u00f2","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.011","article-title":"Real-life results from the overall population and key subgroups within the italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer","volume":"123","author":"Grossi","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0120","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jtho.2018.05.004","article-title":"FIR: Efficacy, Safety, and Biomarker Analysis of a phase II Open-Label Study of Atezolizumab in PD-L1\u2013Selected patients with NSCLC","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0125","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CJI.0000000000000340","article-title":"Efficacy of Pembrolizumab Monotherapy in patients with or without Brain Metastases from Advanced Non\u2013Small Cell Lung Cancer with a PD-L1 Expression \u226550%","volume":"43","author":"Metro","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2025.103014_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2020.11.009","article-title":"Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression","volume":"151","author":"Wakuda","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35864","article-title":"Cemiplimab monotherapy as first\u2010line treatment of patients with brain metastases from advanced non\u2013small cell lung cancer with programmed cell death\u2010ligand 1 \u226550%","volume":"131","author":"Kilickap","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","article-title":"Intracerebral efficacy and tolerance of nivolumab in non\u2013small-cell lung cancer patients with brain metastases","volume":"116","author":"Gauvain","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0155","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0160","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with Pembrolizumab Plus Platinum-based Chemotherapy for patients with NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0165","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II Trial of Atezolizumab combined with Carboplatin and Pemetrexed for patients with Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer with Untreated Brain Metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","article-title":"Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC with Brain Metastases (CAP-BRAIN): a Multicenter, Open-Label, Single-arm, phase 2 Study","volume":"18","author":"Hou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21037\/tlcr-23-687","article-title":"Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy","volume":"13","author":"Zhao","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"25","key":"10.1016\/j.ctrv.2025.103014_b0180","first-page":"00063","article-title":"First-Line Camrelizumab Versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in NSCLC: the CTONG 2003 Randomized Placebo-Controlled Trial","volume":"S1556\u20130864","author":"Li","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006127","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0190","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and Intracranial Outcomes with First-Line Nivolumab Plus Ipilimumab in patients with Metastatic NSCLC and Baseline Brain Metastases from CheckMate 227 Part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0195","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-Line Nivolumab Plus Ipilimumab with Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in patients with Brain Metastases or Select Somatic Mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0205","doi-asserted-by":"crossref","first-page":"15052","DOI":"10.1016\/j.ejca.2024.115052","article-title":"Nivolumab plus ipilimumab with chemotherapy for non\u2013small cell lung cancer with untreated brain metastases: a multicenter single-arm phase 2 trial (NIke, LOGiK 2004)","volume":"212","author":"Tsuchiya-Kawano","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0210","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/ijms25042044","article-title":"Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer","volume":"25","author":"Wen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103014_b0215","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1158\/1535-7163.MCT-23-0416","article-title":"A Review of recent advances in the Molecular Mechanisms underlying Brain Metastasis in Lung Cancer","volume":"23","author":"Guan","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103014_b0220","article-title":"Metastatic brain tumors: from development to cutting-edge treatment","volume":"2025","author":"Tanzhu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.ctrv.2025.103014_b0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0230","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s43018-023-00585-0","article-title":"Leveraging translational insights towards precision medicine approaches for brain metastases","volume":"4","author":"Kim","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0235","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11910-024-01388-1","article-title":"Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: a critical Review","volume":"25","author":"Podder","year":"2025","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ctrv.2025.103014_b0240","doi-asserted-by":"crossref","first-page":"12654","DOI":"10.3390\/ijms222312654","article-title":"Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103014_b0245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0250","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The Microenvironmental Landscape of Brain Tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103014_b0255","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13046-022-02535-7","article-title":"Microglia and metastases to the central nervous system: victim, ravager, or something else?","volume":"41","author":"Caffarel","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0260","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1038\/s41467-022-33365-y","article-title":"The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103014_b0265","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/neuonc\/noad017","article-title":"Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma","volume":"25","author":"Wang","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03530-z","article-title":"Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases","author":"Tagore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jtho.2023.09.276","article-title":"Genetic Intratumor Heterogeneity Remodels the Immune Microenvironment and Induces Immune Evasion in Brain Metastasis of Lung Cancer","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0280","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JS9.0000000000002088","article-title":"Single-cell map of diverse immune phenotypes in the metastatic brain tumor microenvironment of nonsmall-cell lung cancer","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2025.103014_b0285","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2059874","article-title":"Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)","volume":"11","author":"Li","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2025.103014_b0290","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-0798","article-title":"PD-1\/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice","volume":"26","author":"Eguren-Santamaria","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217317","article-title":"Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations","volume":"606","author":"Suay","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2025.103014_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1522508","article-title":"Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer","volume":"15","author":"Xue","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103014_b0305","article-title":"Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103014_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217133","article-title":"Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastases","volume":"598","author":"Li","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2025.103014_b0315","article-title":"Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care","author":"Mansouri","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007474","article-title":"ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models","volume":"11","author":"Jin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00000421-199706000-00011","article-title":"Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents","volume":"20","author":"Qin","year":"1997","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0330","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2017.08.006","article-title":"Blood-tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy","volume":"125","author":"Teng","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0335","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0340","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic Radiotherapy increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0345","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined Radiotherapy and Anti-PD-L1 AntibodySynergistically Enhances Antitumor effectinNon-Small Cell Lung Cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103014_b0350","first-page":"e271","article-title":"Optimum fractionation of radiation to combine PD-1 blockade","volume":"2023","author":"Teng","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.ctrv.2025.103014_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123005","article-title":"Radiotherapy-immunomodulated nanoplatform triggers both hypoxic and normoxic tumor associated antigens generation for robust abscopal effect and sustained immune memory","volume":"316","author":"Li","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ctrv.2025.103014_b0360","doi-asserted-by":"crossref","first-page":"689","DOI":"10.21037\/tlcr-22-515","article-title":"Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Chen","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0365","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cllc.2020.10.014","article-title":"Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in patients with Non-small-cell Lung Cancer Brain Metastases","volume":"22","author":"Enright","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0370","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11060-022-03951-7","article-title":"Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases","volume":"157","author":"Abdulhaleem","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fon-2023-1061","article-title":"Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study","author":"Lu","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0380","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3171\/2019.4.JNS19822","article-title":"Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study","volume":"133","author":"Shepard","year":"2020","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2025.103014_b0385","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","article-title":"Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases","volume":"132","author":"Singh","year":"2020","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2025.103014_b0390","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13014-020-01644-x","article-title":"Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases","volume":"15","author":"Kowalski","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0395","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.21037\/tlcr-22-54","article-title":"Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors","volume":"11","author":"Guo","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0405","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1186\/s12885-024-13110-y","article-title":"The effects of immune checkpoint inhibitors vs. chemotherapy combined with brain radiotherapy in non-small cell lung cancer patients with brain metastases","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0410","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1038\/s41598-025-91863-7","article-title":"A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2025.103014_b0415","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006871","article-title":"Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I\/II trial","volume":"11","author":"Altan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0420","article-title":"Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases","volume":"5","author":"Wong","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2025.103014_b0425","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1470-2045(24)00643-0","article-title":"Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Xu","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108069","article-title":"Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer \u2013 the ETOP 19-21 USZ-STRIKE study","volume":"199","author":"Weller","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0435","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall Survival and Locoregional Disease Control with concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer patients with Brain Metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2025.103014_b0440","first-page":"916","article-title":"Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer","volume":"100","author":"Chen","year":"2018","journal-title":"Melanoma, and Renal Cell Carcinoma International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2025.103014_b0445","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/S0167-8140(18)30805-3","article-title":"OC-0495: Early PD-1 blockade improves disease control for NSCLC brain metastases treated with radiosurgery","volume":"127","author":"Srivastava","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0450","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1002\/cncr.33196","article-title":"Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases","volume":"126","author":"Qian","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0455","doi-asserted-by":"crossref","first-page":"e1399","DOI":"10.1016\/j.wneu.2019.03.110","article-title":"Adverse Radiation effect and Disease Control in patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases","volume":"126","author":"Koenig","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ctrv.2025.103014_b0460","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/cancers14051240","article-title":"Oncologic Outcome and Immune responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding timing and Benefiting Subgroups","volume":"14","author":"Trommer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.103014_b0465","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cllc.2021.06.009","article-title":"Efficacy and Safety of combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer with Brain Metastases: a Systematic Review and Meta-Analysis","volume":"23","author":"Yang","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0470","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","article-title":"Safety of combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer","volume":"13","author":"Hubbeling","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0475","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1186\/s12885-020-07491-z","article-title":"Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases","volume":"20","author":"Gu\u00e9nol\u00e9","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.103014_b0480","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00262-023-03599-w","article-title":"Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis","volume":"73","author":"Blethen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2025.103014_b0485","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of Local Radiation Therapy in Cancer Immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0490","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/neuonc\/now137","article-title":"Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery","volume":"18","author":"Appelboom","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0495","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0500","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1667\/RR3116.1","article-title":"Ablative hypofractionated radiotherapy normalizes tumor vasculature in lewis lung carcinoma mice model","volume":"179","author":"Lan","year":"2013","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0505","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ijrobp.2012.11.003","article-title":"Dose escalation, not \u201cnew biology,\u201d can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer","volume":"85","author":"Brown","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2025.103014_b0510","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared with conventional Fractionated Radiation Therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2025.103014_b0515","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103014_b0520","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccr.2013.10.019","article-title":"A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy","volume":"24","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103014_b0525","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103014_b0530","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0535","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by both Resident and Infiltrating Polyclonal T-cell Populations when combined with PD-1 Blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103014_b0540","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2022.40.16_suppl.2013","article-title":"Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): results of an a priori interim analysis of a multicenter phase I trial","volume":"40","author":"McClelland","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0545","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1007\/s00330-020-07514-0","article-title":"Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis","volume":"31","author":"Kim","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ctrv.2025.103014_b0550","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and Symptomatic Radiation Necrosis in patients with Brain Metastases Treated with Stereotactic Radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0555","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0560","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0565","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3171\/2022.9.JNS221896","article-title":"Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone","volume":"138","author":"Dohm","year":"2023","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2025.103014_b0570","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijrobp.2020.06.057","article-title":"Predictors of adverse Radiation effect in Brain Metastasis patients Treated with Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy","volume":"108","author":"Helis","year":"2020","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2025.103014_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109920","article-title":"Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy","volume":"189","author":"Hall","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0580","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0585","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0590","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103014_b0595","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103014_b0600","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41467-021-21789-x","article-title":"Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment","volume":"12","author":"Rubio-Perez","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103014_b0605","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03538-5","article-title":"Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases","author":"Zheng","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103014_b0610","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2290790","article-title":"Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases","volume":"13","author":"Li","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2025.103014_b0615","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/cac2.12410","article-title":"Integrated circulating tumor DNA and T cell repertoire predict radiotherapeutic response and outcome in non\u2010small cell lung cancer patients with brain metastasis","volume":"43","author":"Peng","year":"2023","journal-title":"Cancer Commun (Lond)"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:54:29Z","timestamp":1762016069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":123,"alternative-id":["S0305737225001367"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103014","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities and challenges for non\u2013small cell lung cancer brain metastases in the immunotherapy era","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103014"}}